The Role of Diabetes Mellitus in the Malignant Pancreatic Cyst Neoplasm Diagnosis and Prognosis

References

• van Huijgevoort NCM, Del Chiaro M, Wolfgang CL, van Hooft JE, Besselink MG. Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines. Nat Rev Gastroenterol Hepatol. 2019;16(11):676–689. doi:10.1038/s41575-019-0195-x
   PubMed Web of Science ®Google Scholar
• Volkan Adsay N. Cystic lesions of the pancreas. Mod Pathol. 2007;20(Suppl 1):S71–93. doi:10.1038/modpathol.3800706
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921. doi:10.1158/0008-5472.CAN-14-0155
   PubMed Web of Science ®Google Scholar
• Yamada S, Fujii T, Murotani K, et al. Comparison of the international consensus guidelines for predicting malignancy in intraductal papillary mucinous neoplasms. Surgery. 2016;159(3):878–884. doi:10.1016/j.surg.2015.08.042
   PubMed Web of Science ®Google Scholar
• Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes. 2017;66(5):1103–1110. doi:10.2337/db16-1477
   PubMed Web of Science ®Google Scholar
• Ma J, Wang J, Ge L, Long B, Zhang J. The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis. Acta Diabetol. 2019;56(10):1103–1111. doi:10.1007/s00592-019-01337-2
   PubMed Web of Science ®Google Scholar
• Lv X, Qiao W, Leng Y, Wu L, Zhou Y. Impact of diabetes mellitus on clinical outcomes of pancreatic cancer after surgical resection: a systematic review and meta-analysis. PLoS One. 2017;12(2):e0171370. doi:10.1371/journal.pone.0171370
   PubMed Web of Science ®Google Scholar
• Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol. 2007;102(10):2157–2163. doi:10.1111/j.1572-0241.2007.01480.x
   PubMed Web of Science ®Google Scholar
• Sharma A, Kandlakunta H, Nagpal SJS, et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes. Gastroenterology. 2018;155(3):730–739.e733. doi:10.1053/j.gastro.2018.05.023
   PubMed Web of Science ®Google Scholar
• Pergolini I, Jäger C, Safak O, et al. Diabetes and weight loss are associated with malignancies in patients with intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 2021;19(1):171–179. doi:10.1016/j.cgh.2020.04.090
   PubMed Web of Science ®Google Scholar
• Morales-Oyarvide V, Mino-Kenudson M, Ferrone CR, et al. Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology. 2017;17(6):920–926. doi:10.1016/j.pan.2017.08.073
   PubMed Web of Science ®Google Scholar
• Schweber AB, Brooks C, Agarunov E, et al. New onset diabetes predicts progression of low risk pancreatic mucinous cysts. Pancreatology. 2020;20(8):1755–1763. doi:10.1016/j.pan.2020.09.015
   PubMed Web of Science ®Google Scholar
• European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67(5):789–804. doi:10.1136/gutjnl-2018-316027
   PubMed Web of Science ®Google Scholar
• Ledolter J, Kardon RH. Focus on data: statistical design of experiments and sample size selection using power analysis. Invest Ophthalmol Vis Sci. 2020;61(8):11. doi:10.1167/iovs.61.8.11
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–S27.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–493. doi:10.2337/dci19-0066
   PubMed Web of Science ®Google Scholar
• Yuan C, Rubinson DA, Qian ZR, et al. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol. 2015;33(1):29–35. doi:10.1200/JCO.2014.57.5688
   PubMed Web of Science ®Google Scholar
• Yuan C, Babic A, Khalaf N, et al. Diabetes, weight change, and pancreatic cancer risk. JAMA Oncology. 2020;6(10):e202948–e202948. doi:10.1001/jamaoncol.2020.2948
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. doi:10.1007/BF00280883
   PubMed Web of Science ®Google Scholar
• Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–197. doi:10.1016/j.pan.2012.04.004
   PubMed Web of Science ®Google Scholar
• Yu J, Sadakari Y, Shindo K, et al. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut. 2017;66(9):1677–1687. doi:10.1136/gutjnl-2015-311166
   PubMed Web of Science ®Google Scholar
• Bardeesy N, Cheng KH, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20(22):3130–3146. doi:10.1101/gad.1478706
   PubMed Web of Science ®Google Scholar
• Noë M, Niknafs N, Fischer CG, et al. Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nat Commun. 2020;11(1):4085. doi:10.1038/s41467-020-17917-8
   PubMed Web of Science ®Google Scholar
• Hu HF, Ye Z, Qin Y, et al. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol Sin. 2021;42(11):1725–1741. doi:10.1038/s41401-020-00584-2
   PubMed Web of Science ®Google Scholar
• Deng J, Guo Y, Du J, et al. The intricate crosstalk between insulin and pancreatic ductal adenocarcinoma: a review from clinical to molecular. Front Cell Dev Biol. 2022;10:844028. doi:10.3389/fcell.2022.844028
   PubMed Web of Science ®Google Scholar
• Huang W, Navarro-Serer B, Jeong YJ, et al. Pattern of invasion in human pancreatic cancer organoids is associated with Loss of SMAD4 and clinical outcome. Cancer Res. 2020;80(13):2804–2817. doi:10.1158/0008-5472.CAN-19-1523
   PubMed Web of Science ®Google Scholar
• Shen W, Tao G-Q, Zhang Y, Cai B, Sun J, Tian ZQ. TGF-Β in pancreatic cancer initiation and progression: two sides of the same coin. Cell Biosci. 2017;7:39. doi:10.1186/s13578-017-0168-0
   PubMed Web of Science ®Google Scholar
• Parajuli P, Nguyen TL, Prunier C, Razzaque MS, Xu K, Atfi A. Pancreatic cancer triggers diabetes through TGF-β-mediated selective depletion of islet β-cells. Life Sci Alliance. 2020;3:e201900573. doi:10.26508/lsa.201900573
   PubMed Web of Science ®Google Scholar
• Ma P, Tang WG, Hu JW, et al. HSP4 triggers epithelial-mesenchymal transition and promotes motility capacities of hepatocellular carcinoma cells via activating AKT. Liver Int. 2020;40(5):1211–1223. doi:10.1111/liv.14410
   PubMed Web of Science ®Google Scholar
• Natsuizaka M, Ozasa M, Darmanin S, et al. Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res. 2007;313(15):3337–3348. doi:10.1016/j.yexcr.2007.06.013
   PubMed Web of Science ®Google Scholar
• Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378–389. doi:10.1016/j.apsb.2015.05.007
   PubMed Web of Science ®Google Scholar
• Cao N, Tang X, Gao R, et al. Galectin-3 participates in PASMC migration and proliferation by interacting with TGF-β1. Life Sci. 2021;274:119347. doi:10.1016/j.lfs.2021.119347
   PubMed Web of Science ®Google Scholar
• Sagar G, Sah RP, Javeed N, et al. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 2016;65(7):1165–1174. doi:10.1136/gutjnl-2014-308350
   PubMed Web of Science ®Google Scholar
• Liao WC, Huang BS, Yu YH, et al. Galectin-3 and S100A9: novel diabetogenic factors mediating pancreatic cancer-associated diabetes. Diabetes Care. 2019;42(9):1752–1759. doi:10.2337/dc19-0217
   PubMed Web of Science ®Google Scholar
• Chu CK, Mazo AE, Sarmiento JM, et al. Impact of diabetes mellitus on perioperative outcomes after resection for pancreatic adenocarcinoma. J Am Coll Surg. 2010;210(4):463–473. doi:10.1016/j.jamcollsurg.2009.12.029
   PubMed Web of Science ®Google Scholar
• Peng YP, Zhu XL, Yin LD, et al. Risk factors of postoperative pancreatic fistula in patients after distal pancreatectomy: a systematic review and meta-analysis. Sci Rep. 2017;7(1):185. doi:10.1038/s41598-017-00311-8
   PubMed Web of Science ®Google Scholar
• Xia X, Huang C, Cen G, Qiu ZJ. Preoperative diabetes as a protective factor for pancreatic fistula after pancreaticoduodenectomy: a meta-analysis. Hepatobiliary Pancreat Dis Int. 2015;14(2):132–138. doi:10.1016/S1499-3872(15)60330-7
   PubMed Web of Science ®Google Scholar
• Mao Y, Tao M, Jia X, et al. Effect of diabetes mellitus on survival in patients with pancreatic cancer: a systematic review and meta-analysis. Sci Rep. 2015;5:17102. doi:10.1038/srep17102
   PubMed Web of Science ®Google Scholar
• Shingyoji A, Mikata R, Ogasawara S, et al. Diverse transitions in diabetes status during the clinical course of patients with resectable pancreatic cancer. Jpn J Clin Oncol. 2020;50(12):1403–1411. doi:10.1093/jjco/hyaa136
   PubMed Web of Science ®Google Scholar
• Cho J, Scragg R, Pandol SJ, Goodarzi MO, Petrov MS. Antidiabetic medications and mortality risk in individuals with pancreatic cancer–related diabetes and postpancreatitis diabetes: a nationwide cohort study. Diabetes Care. 2019;42(9):1675. doi:10.2337/dc19-0145
   PubMed Web of Science ®Google Scholar
• Amin S, Mhango G, Lin J, et al. Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. Am J Gastroenterol. 2016;111(9):1350–1357. doi:10.1038/ajg.2016.288
   PubMed Web of Science ®Google Scholar
• Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):510–519; quiz 520. doi:10.1038/ajg.2013.7
   Web of Science ®Google Scholar
• Chen K, Qian W, Jiang Z, et al. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer. 2017;16(1):131. doi:10.1186/s12943-017-0701-0
   PubMed Web of Science ®Google Scholar